FDA approves Ventana Medical's breast cancer test

06/15/2011 | Wall Street Journal, The

Ventana Medical Systems, a Roche Holding subsidiary, has received FDA approval for its Inform Dual ISH genetic test, which is designed to identify patients who are likely to benefit from Herceptin, Genentech's breast cancer drug. The test works by looking for the presence of the HER2 gene in patients' tumor samples.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ